Madrigal Pharmaceuticals (MDGL) Free Cash Flow (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Free Cash Flow data on file, last reported at -$171.3 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 92.69% year-over-year to -$171.3 million in Q1 2026; TTM through Mar 2026 was -$272.4 million, a 31.28% increase from a year earlier, with the FY2025 full-year figure at -$190.0 million, up 58.42% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$171.3 million, down from -$133.2 million in the prior quarter.
• Over the last five years, Free Cash Flow for MDGL reached as high as $79.1 million in Q3 2025 and fell as low as -$171.3 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$80.5 million across 5 years, with a median of -$81.0 million in 2023.
• Across the five-year window, Free Cash Flow soared 218.99% in 2025 and tumbled 92.69% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$58.5 million in 2022, then sank by 38.3% to -$81.0 million in 2023, then sank by 30.85% to -$105.9 million in 2024, then dropped by 25.72% to -$133.2 million in 2025, then slipped by 28.59% to -$171.3 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$171.3 million in Q1 2026, -$133.2 million in Q4 2025, and $79.1 million in Q3 2025.